We are live on ! Find out more
BNR

Burning Rock Biotech
BNR

Fund managers haven’t disclosed any holdings of BNR yet.

BNR Hedge Fund Activity: Q1 2026 in Review

16 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q1 2026, worth a combined $27.4M — down 22% from $34.9M a quarter earlier.

Fund positioning in BNR was balanced in Q1 2026: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 7 trimmed.

The largest buyer was Kynam Capital Management, adding an estimated $6.09M. The largest seller was CRCM LP, cutting an estimated $5.48M.

  • 16 institutional investors held Burning Rock Biotech (BNR) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $27.4M of Burning Rock Biotech stock for Q1 2026, down 22% quarter-over-quarter.
  • 3 funds opened new Burning Rock Biotech positions in Q1 2026 and 3 closed out, a net change of 0 holders.
  • The largest Burning Rock Biotech buyer in Q1 2026 was Kynam Capital Management, an estimated $6.09M added.
  • The largest Burning Rock Biotech seller in Q1 2026 was CRCM LP, an estimated $5.48M sold.

Based on aggregated 13F filings for Q1 2026.